rociverine and Colonic-Diseases--Functional

Forty outpatients of both sexes suffering from irritable colon syndrome were treated for four weeks with rociverine, an antispastic agent with anti-muscarinic and direct miolytic activities, at a dose of 20 mg x 3. The aim of the study was to assess the efficacy and tolerability of this dose since the drug is normally administered at a dose of 30-40 mg a day. The efficacy of treatment was assessed on the basis of the evolution of clinical symptoms, whereas its tolerability was evaluated in both clinical and biohumoral terms. The results of the study showed that a dose of 60 mg/die of causes a marked and significant reduction of the typical symptoms of irritable colon, in particular abdominal pain, with no variation in analytical findings and a small number of clinically unimportant side effects.

Topics: Adult; Bridged Bicyclo Compounds; Colonic Diseases, Functional; Cyclohexanecarboxylic Acids; Female; Humans; Male; Middle Aged; Parasympatholytics

Topics: Adult; Aged; Bridged Bicyclo Compounds; Bridged-Ring Compounds; Colonic Diseases, Functional; Cyclohexanecarboxylic Acids; Endoscopy; Female; Humans; Male; Middle Aged; Nausea; Parasympatholytics; Vomiting